SAGE Therapeutics (NASDAQ:SAGE) posted its earnings results on Tuesday. The biopharmaceutical company reported ($3.28) EPS for the quarter, topping the consensus estimate of ($3.32) by $0.04, Briefing.com reports. The company had revenue of $0.87 million for the quarter, compared to analyst estimates of $0.27 million. The firm’s revenue was down 99.0% on a year-over-year basis. During the same period last year, the business earned ($0.36) earnings per share.
SAGE stock traded up $3.13 during mid-day trading on Tuesday, reaching $159.77. 10,137 shares of the company’s stock were exchanged, compared to its average volume of 402,957. The firm has a market capitalization of $8.13 billion, a P/E ratio of -19.84 and a beta of 2.53. The firm has a 50 day moving average of $177.36. The company has a current ratio of 20.06, a quick ratio of 20.06 and a debt-to-equity ratio of 0.03. SAGE Therapeutics has a 12-month low of $79.88 and a 12-month high of $193.56.
Several research firms recently commented on SAGE. Jefferies Financial Group began coverage on SAGE Therapeutics in a report on Thursday, April 25th. They set a “buy” rating and a $195.00 target price on the stock. BidaskClub lowered SAGE Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 27th. ValuEngine lowered SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 18th. Canaccord Genuity set a $220.00 target price on SAGE Therapeutics and gave the stock a “buy” rating in a report on Monday, April 8th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, July 24th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $204.46.
SAGE Therapeutics Company Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
Featured Story: How to use beta for portfolio diversification
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.